Niddazol (Itraconazole)

Itraconazole, the active ingredient in Niddazol, is an azole antifungal presented as an oral formulation for systemic use. It is employed to treat a range of fungal infections, including invasive mycoses, candidiasis and dermatophytosis, in adult patients requiring prescription therapy.

GNH USA supplies Niddazol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. All shipments are handled through regulated channels to ensure compliance with local regulations.

Itraconazole is an azole antifungal used to treat systemic and superficial fungal infections.

- Systemic mycoses (e.g., aspergillosis, blastomycosis, histoplasmosis): eradicates invasive fungal organisms and improves clinical outcomes. - Candidiasis: treats oral, esophageal and systemic Candida infections, reducing fungal burden. - Dermatophytosis: resolves skin and nail infections caused by dermatophyte fungi, promoting lesion healing.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Rash: skin erythema or pruritus. - Taste disturbance: altered taste perception.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac failure: worsening of pre‑existing heart conditions. - Visual disturbances: blurred vision or photophobia.

Itraconazole requires careful clinical monitoring before and during therapy. - Hepatic function: assess baseline liver enzymes and monitor periodically. - Renal function: evaluate kidney status, especially in patients with concomitant nephrotoxic drugs. - Drug interactions: review all concomitant medications for CYP3A4 involvement. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Itraconazole has several clinically significant drug interactions.

Major Interactions (Avoid): - Rifampin: induces metabolism, markedly lowering itraconazole exposure. - Ketoconazole: combined hepatotoxic risk; avoid co‑administration. - St. John’s wort: strong CYP3A4 inducer, reduces efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may increase anticoagulant effect; monitor INR. - Simvastatin: increased statin levels raise risk of myopathy; consider dose adjustment.